The study aimed to determine whether treatment with high dose ocrelizumab would provide an additional benefit in slowing disability progression.

Roche (OTCQX:RHHBY) (OTCQX:RHHBF) announced Wednesday that a Phase 3 trial for a high-dose version of its multiple sclerosis ...

Researchers found that higher ocrelizumab exposure over 10 years was associated with less risk of disability progression in ...

Roche’s phase III MUSETTE trial of Ocrevus high dose in people with relapsing multiple sclerosis fails to meet primary endpoint: Basel Friday, April 4, 2025, 11:00 Hrs [IST] Roc ...

Roche Holdings AG (OTC:RHHBY) on Wednesday announced data from MUSETTE Phase 3 trial of a high dose of Ocrevus (ocrelizumab) ...

Please provide your email address to receive an email when new articles are posted on . Ocrelizumab reduced the number and size of MS-related cortical lesions. Data synthesis featuring a mix of ...

You can also talk with your doctor about the cost of the drug. Ocrevus contains the active ingredient ocrelizumab, and it’s available only as a brand-name biologic drug. It doesn’t come in a ...

Current clinical trials are investigating treatments like tolebrutinib, fingolimod, ocrelizumab, ublituximab, and fenebrutinib, focusing on safety, efficacy, and specific patient demographics.

Ocrevus IV and Ocrevus subcutaneous (SC; marketed as Ocrevus Zunovo® [ocrelizumab hyaluronidase-ocsq] in the U.S.) are the only therapies approved for both RMS (including relapsing-remitting ...

The CHIMES study examines the effectiveness of ocrelizumab in Black and Hispanic MS patients. After 24 weeks, the trial showed MRI outcomes comparable to the pivotal phase 3 ocrelizumab OPERA ...

However, as most data is registry-based and previous trials did not directly compare aHSCT with the most efficacious DMTs, Alemtuzumab, Ocrelizumab, Cladribine and Ofatumumab, questions remain over ...

Register for free now. Roche Holdings AG RHHBY on Wednesday announced data from MUSETTE Phase 3 trial of a high dose of Ocrevus (ocrelizumab) intravenous (IV) infusion in adult patients with ...